• GOT1 Inhibition by Ziprasidone Disrupts Redox Balance in PDA

  2026-04-25

  This study demonstrates that ziprasidone acts as a potent non-competitive inhibitor of GOT1, disrupting glutamine metabolism and redox homeostasis in pancreatic ductal adenocarcinoma (PDAC). The findings highlight GOT1 inhibition as a promising metabolic intervention for PDAC, with direct implications for redox biology research.

• Optimizing Chondrogenic Differentiation Assays with Alcian B

  2026-04-24

  Discover how the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 empowers advanced mucosubstance detection and robust chondrogenic differentiation assays. This article uniquely bridges analytical rigor with practical guidance for optimizing stem cell and tissue histology workflows.

• Thiazovivin: Practical Guidance for ROCK Inhibition in Stem

  2026-04-24

  Thiazovivin is a small molecule ROCK inhibitor optimized for improving the efficiency of fibroblast reprogramming and enhancing human embryonic stem cell (hESC) survival during induced pluripotent stem cell (iPSC) generation. It is not intended for diagnostic, therapeutic, or long-term storage applications, but is tailored for controlled research workflows requiring short-term ROCK pathway modulation.

• Targeting DHHC9-STRN4 Palmitoylation Suppresses YAP-Driven M

  2026-04-23

  This study identifies DHHC9-mediated STRN4 palmitoylation as a critical regulator of YAP-driven metastasis in adenocarcinoma. By pharmacologically inhibiting DHHC9, the authors demonstrate suppression of cancer cell migration, highlighting a new axis and therapeutic target for metastatic cancer intervention.

• Tacrolimus (FK506): Precision in Transplantation Immunology

  2026-04-23

  Tacrolimus (FK506) from APExBIO stands out as a potent, selective calcineurin inhibitor, enabling high-fidelity immune response modulation in both in vitro and in vivo models. With robust solubility and nanomolar efficacy, it offers experimental advantages for transplantation immunology and autoimmune disease model development.

• Proteinase K Unveiled: Advanced Enzyme Dynamics for Genomic

  2026-04-22

  Explore the science of Proteinase K as a broad-spectrum serine protease for uncompromised DNA integrity. This article delivers a distinctive, mechanistic perspective and protocol guidance beyond standard usage guides.

• L1023 Anti-Cancer Compound Library: Pathway Profiling and Pr

  2026-04-22

  Explore how the L1023 Anti-Cancer Compound Library advances cancer research through pathway-driven screening and biomarker discovery. Learn how its design empowers precision oncology, with a focus on predictive targets like PLAC1.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-04-21

  Schwartz (2022) introduces a rigorous framework to distinguish between proliferative arrest and cytotoxicity in anti-cancer drug assays, revealing that most agents exert complex, time-dependent effects on both cell growth and death. These insights enable more precise evaluation of candidate compounds, supporting improved translational relevance for preclinical cancer research.

• PSA-CD56/Siglec-7 Axis Drives Immune Evasion in ccRCC

  2026-04-21

  This study identifies polysialylated CD56 as a key glyco-immune checkpoint mediating immune evasion in clear cell renal cell carcinoma (ccRCC) via interaction with Siglec-7 on CD8+ T cells. The findings provide a mechanistic basis for immunotherapy resistance in ccRCC and highlight a novel therapeutic target for restoring antitumor immunity.

• Ruxolitinib (INCB018424): Advanced Workflows for Immune Prof

  2026-04-20

  Ruxolitinib (INCB018424) empowers researchers to dissect JAK-STAT pathway inhibition and redefine immune profiling in challenging tumor microenvironments. This article translates recent high-dimensional cytometry advances into actionable protocols and troubleshooting tactics, with a special focus on combination immunotherapy and myeloproliferative disorder research.

• Oligo (dT) 25 Beads: Technical Guide for mRNA Purification

  2026-04-20

  Oligo (dT) 25 Beads provide a reliable, magnetic bead-based method for isolating eukaryotic mRNA via polyA tail capture. This product is optimal for obtaining high-quality mRNA for downstream applications such as RT-PCR, cDNA synthesis, and next-generation sequencing. It is not intended for use with prokaryotic RNA or workflows that require non-polyadenylated RNA species.

• Tamsulosin in Urological Research: Protocols, Insights & Wor

  2026-04-19

  Tamsulosin, a selective α₁A-adrenergic receptor antagonist, is transforming urological and smooth muscle research with robust solubility, reproducible efficacy, and well-defined dosing protocols. By leveraging recent meta-analytic findings and scenario-driven workflows, APExBIO’s Tamsulosin (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide empowers researchers to overcome common barriers in GPCR signaling and urinary retention studies.

• Resazurin Sodium Salt: Advancing Translational Cell Metaboli

  2026-04-18

  This thought-leadership article explores the mechanistic and strategic foundations of using Resazurin sodium salt as a gold-standard fluorogenic oxidation-reduction indicator in translational research. By bridging metabolic pathway interrogation—exemplified by liver fibrosis models targeting glutamine metabolism—with rigorous assay optimization and workflow guidance, we demonstrate how APExBIO’s Resazurin sodium salt empowers researchers to generate high-confidence, clinically relevant data. The piece differentiates itself by integrating evidence-based protocol recommendations, competitive analysis, and a forward-looking perspective on assay innovation, surpassing the scope of traditional product pages.

• AMD-070 Hydrochloride: Protocols and Troubleshooting for CXC

  2026-04-17

  Mavorixafor hydrochloride (AMD-070 hydrochloride) is a potent, selective CXCR4 antagonist that empowers researchers to model, modulate, and troubleshoot CXCR4/CXCL12-driven cell migration and immune dysfunction. Its robust solubility and safety profile, combined with advanced workflow guidance, make it a premier choice for translational studies in hematology, immunology, and HIV entry inhibition.

• Pomalidomide (CC-4047) in Hematological Malignancy Research

  2026-04-16

  Pomalidomide (CC-4047) empowers researchers to dissect tumor microenvironment dynamics and erythroid differentiation in hematological malignancy models. This article delivers evidence-driven workflow enhancements, troubleshooting guidance, and actionable protocol parameters for maximizing reproducibility in multiple myeloma and related studies.

14667 records 1/978 page Next 12345 下5页 Last page